IDO1 Antikörper

Produktnummer ABIN1169196

Zitiert in 5+ Publikationen. Dieser Anti-IDO1-Antikörper ist ein Kaninchen-Polyklonal-Antikörper zum Nachweis von IDO1 in WB, ELISA, ICC und FACS. Geeignet für Human.

Kurzübersicht für IDO1 Antikörper (ABIN1169196)

Target: IDO1 (Indoleamine 2,3-Dioxygenase 1 (IDO1))

Reaktivität: Human

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser IDO1 Antikörper ist unkonjugiert

Applikation: Western Blotting (WB), ELISA, Immunocytochemistry (ICC), Flow Cytometry (FACS)

Produktdetails anti-IDO1 Antikörper

Spezifität: Recognizes human IDO. Detects a band of ~45 kDa by Western blot.

Kreuzreaktivität: Human

Sterilität: 0.2 μm filtered

Immunogen: Recombinant human IDO.

Anwendungsinformationen

Applikationshinweise: Optimal working dilution should be determined by the investigator.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Konzentration: Lot specific

Buffer: 0.2μm-filtered solution in PBS, pH 7.4. Contains no preservatives.

Konservierungsmittel: Without preservative

Lagerung: 4 °C,-20 °C

Informationen zur Lagerung: Short Term Storage: +4°C
Long Term Storage: -20°C
Stable for at least 6 months after receipt when stored at -20°C.

Haltbarkeit: 6 months

Referenzen für anti-IDO1 Antikörper (ABIN1169196)

Pietra, Manzini, Rivara, Vitale, Cantoni, Petretto, Balsamo, Conte, Benelli, Minghelli, Solari, Gualco, Queirolo, Moretta, Mingari: "Melanoma cells inhibit natural killer cell function by modulating the expression of activating receptors and cytolytic activity." in: Cancer research, Vol. 72, Issue 6, pp. 1407-15, (2012) (PubMed).

Opitz, Litzenburger, Opitz, Sahm, Ochs, Lutz, Wick, Platten: "The indoleamine-2,3-dioxygenase (IDO) inhibitor 1-methyl-D-tryptophan upregulates IDO1 in human cancer cells." in: PLoS ONE, Vol. 6, Issue 5, pp. e19823, (2011) (PubMed).

Curti, Trabanelli, Onofri, Aluigi, Salvestrini, Ocadlikova, Evangelisti, Rutella, De Cristofaro, Ottaviani, Baccarani, Lemoli: "Indoleamine 2,3-dioxygenase-expressing leukemic dendritic cells impair a leukemia-specific immune response by inducing potent T regulatory cells." in: Haematologica, Vol. 95, Issue 12, pp. 2022-30, (2010) (PubMed).

Maby-El Hajjami, Amé-Thomas, Pangault, Tribut, DeVos, Jean, Bescher, Monvoisin, Dulong, Lamy, Fest, Tarte: "Functional alteration of the lymphoma stromal cell niche by the cytokine context: role of indoleamine-2,3 dioxygenase." in: Cancer research, Vol. 69, Issue 7, pp. 3228-37, (2009) (PubMed).

Boasso, Herbeuval, Hardy, Anderson, Dolan, Fuchs, Shearer: "HIV inhibits CD4+ T-cell proliferation by inducing indoleamine 2,3-dioxygenase in plasmacytoid dendritic cells." in: Blood, Vol. 109, Issue 8, pp. 3351-9, (2007) (PubMed).

Details zu IDO1

Target: IDO1 (Indoleamine 2,3-Dioxygenase 1 (IDO1))

Andere Bezeichnung: IDO

Hintergrund: IDO catalyzes the first and rate-limiting step in the main pathway of human tryptophan catabolism, the kynurenine pathway. Proinflammatory mediators, such as endotoxin and IFN-gamma induce the expression of IDO in several tissues. IDO-dependent suppression of T-cell responses might function as natural immunoregulatory mechanism. Physiological IDO activity has been implicated in T-cell tolerance to tumors, dysfunctional selftolerance in non-obese diabetic (NOD) mice, and as a protective negative regulator in autoimmune disorders.

UniProt: P14902

Pathways: Activated T Cell Proliferation